Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience

BACKGROUND: Triple-negative breast carcinoma (TNBC) patients do not benefit from hormone- or human epidermal growth factor receptor 2- (HER2-) targeted therapies. Accurate testing is pivotal for these patients. METHODS: TNBC cases that were retested at our institution during a 3-year period were eva...

Descripción completa

Detalles Bibliográficos
Autores principales: De Jesus, Jose, Rosa, Marilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788018/
https://www.ncbi.nlm.nih.gov/pubmed/31632197
http://dx.doi.org/10.1186/s12935-019-0987-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788018/
https://www.ncbi.nlm.nih.gov/pubmed/31632197
http://dx.doi.org/10.1186/s12935-019-0987-7

Ejemplares similares